Regeneron (REGN) Tops Q1 EPS by 47c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Regeneron Reports First Quarter 2020 Financial and Operating Results
May 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., May 5, 2020 /PRNewswire/ --
First quarter 2020 revenues increased 33% to $1.83 billion versus first quarter 2019(4) First quarter EYLEA® U.S. net sales increased 9% to $1.17 billion versus first quarter 2019 First quarter Dupixent® global net sales(2), which are recorded by Sanofi, increased 129% to $855 million versus first quarter 2019 First quarter 2020 GAAP diluted EPS was $5.43 and non-GAAP diluted EPS(1) was $6.60 Libtayo® Phase 3 trial in first-line non-small cell lung cancer stopped early due to positive overall survival benefit with regulatory submissions planned later this year Libtayo showed... More
